Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07002034 · ClinicalTrials.gov registry record · Phase 2
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
A Phase 2 study of Adjustment Disorder, sponsored by Reunion Neuroscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07002034: Recruiting Phase 2 study of Adjustment Disorder, sponsored by Reunion Neuroscience.
NCT07002034 is a Phase 2 study of Adjustment Disorder that is actively recruiting participants, run by Reunion Neuroscience. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07002034, a Phase 2 study of Adjustment Disorder, is actively recruiting participants, sponsored by Reunion Neuroscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Primary Outcome
Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.
Conditions Studied
Interventions
- DRUG RE104 for Injection
Study Locations (20)
California
- Kadima Neuropsychiatry Institute - San Diego
- Providence Medical Foundation - Santa Rosa
Maryland
- Sunstone Therapies, PC - Rockville
- Sheppard Pratt - Towson
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University, Department of Psychiatry - Columbus
Alabama
- UAB, Psychiatry and Behavioral Neurology - Birmingham
Arizona
- University of Arizona - Tucson
Colorado
- University of Colorado - Aurora
Florida
- University of South Florida, Department of Psychiatry and Behavioral Neuroscience - Tampa
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT07002034 shows while recruiting
NCT07002034 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Adjustment Disorder appearing as the primary indexed condition, and to 1 intervention - of which RE104 for Injection is the first listed.
NCT07002034 names 20 study sites across 17 states, led by California, Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT07002034 about?
NCT07002034 is a clinical study titled "RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses". The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multi...
What is the current status of trial NCT07002034?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-07-30. Estimated completion is 2026-12.
What conditions does trial NCT07002034 study?
This clinical trial studies the following conditions: Adjustment Disorder.
What interventions are being tested in trial NCT07002034?
The interventions under investigation include: RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT07002034?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07002034 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adjustment Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07002034's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI